CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
Refresh Optive +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03380624
NCT03380624Phase 4Completed
CompareCT.gov

Tear Lipid Layer Thickness With Emollient Eye Drops

Ohio State University·interventional·Posted Dec 21, 2017·Updated Feb 3, 2021

In Brief

A Phase 4 clinical trial evaluating Refresh Optive and Refresh Optive MEGA-3 for Dry Eye Syndromes. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Crossover comparison of lipid layer thickness with two artificial tear formulations

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 21, 2017
Enrollment StartMar 1, 2017
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.5 years ago

Interventions

Refresh Optivedrug

Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose

Refresh Optive MEGA-3drug

Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose